GRENOBLE, France, Nov. 4, 2014 /PRNewswire/ — ImmunID announced today that an abstract has been accepted for oral presentation at the Society for Immunotherapy of Cancer Annual Meeting being held November 6 to 9, 2014 in National Harbor, MD. The abstract titled "T cell receptor diversity evaluation to predict patient response to Ipilimumab in metastatic melanoma" will be presented Saturday, November 8, at 5:10 pm during the Session "High Throughput Technologies: Determinants of the Immune Response to Cancer" by Dr. Michael Postow, a medical oncologist in the Melanoma and Immunotherapeutics Service at Memorial Sloan Kettering Cancer Center and lead author on the study. In addition, a poster (#156) will be presented during the annual meeting poster sessions.
"We welcome the chance to interact with the cancer immunotherapy community about the exciting preliminary data about T cell receptor diversity and response to Ipilimumab in patients with metastatic melanoma. This is an area of high unmet medical need and this work could ultimately make a major contribution to cancer immunotherapy by the identification of immune competent patients who may be more likely to respond to treatment," said Dr. Postow.
"We are honored to be selected for an oral presentation at SITC. Our inclusion in SITC Annual Meeting program is further recognition of our innovative approach to measure the competence of the patient's immune system to fight cancers and other life threatening diseases," said Bernhard Sixt, ImmunID's Chairman and Chief Executive Officer.
The yearly SITC Annual Meeting & Associated Programs serve as the primary SITC organized events and the premier destination for scientific exchange, education, and networking in the cancer immunotherapy community. Basic researchers, clinicians, government representatives, industry leaders, students, postdoctoral fellows and allied health professionals dedicated to improving patient outcomes through cancer immunotherapy will all come together at SITC 2014 to experience cutting edge research, education and training that serves as the catalyst for advancement of the field.
For more information about the Society for Immunotherapy of Cancer Annual Meeting, please click here.
About ImmunID
ImmunID has been a pioneer in the immune molecular diagnostic field since 2005. Its two clinical products ImmunTraCkeR® and ImmunIG® evaluate patient immune competence based on T and B cell repertoire diversity, respectively. The company is establishing ImmunTraCkeR® as the general immune companion diagnostic for all immunotherapies and setting the general immune molecular diagnostics standard globally. ImmunID collaborates with leading clinical research centers and biopharmaceutical companies worldwide to further validate ImmunTraCkeR® as an immune companion diagnostic test for new immunotherapies and to widen clinical utility of its products. The company is ISO9001 certified and runs an ISO13485 accredited production and R&D facility in the MINATEC high-tech campus in Grenoble, France. In addition, ImmunID has applied for CAP accreditation / CLIA certification of its central lab to be able to provide ImmunTraCkeR® routinely to clinical patients in the United States.
www.immunid.com – Follow ImmunID on Twitter: @ImmunID
For further information, please contact:
Bernhard Sixt
Chairman and CEO
Email
Phone: +33 438 785 770